Francis Barth

Publications

• 2018
• Kinetics of human cannabinoid 1 (CB1) receptor antagonists: Structure-kinetics relationships (SKR) and implications for insurmountable antagonism

  L. Xia, H. de Vries, X. Yang, E. B. Lenselink, A. Kyrizaki, F. Barth, .... (2018)

  Biochemical Pharmacology, 151, 166-179.
• 2014
• Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor

  L. Hortala, J. Arnaud, P. Roux, D. Oustric, L. Boulu, F. Oury-Donat, .... (2014)

  Bioorganic & Medicinal Chemistry Letters, 24(1), 283–287.
• 2013
• Mastering tricyclic ring systems for desirable functional cannabinoid activity

  R. R. Petrov, L. Knight, S. - R. Chen, J. Wager-Miller, S. W. McDaniel, F. Diaz, .... (2013)

  European Journal of Medicinal Chemistry, 69(C), 881–907.
• 2010
• Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif

  L. Hortala, M. Rinaldi-Carmona, C. Congy, L. Boulu, F. Sadoun, G. Fabre, .... (2010)

  Bioorganic & Medicinal Chemistry Letters, 20(15), 4573–4577.
• 2008
• Role of cannabinoid receptors in regulation of cardiac tolerance to ischemia and reperfusion

  O. V. Lasukova, L. N. Maslov, S. Y. Ermakov, D. Crawford, F. Barth, A. V. Krylatov, & L. O. Hanus. (2008)

  Biology Bulletin, 35(4), 404–410.
• 2007
• [Pharmacology of cannabinoid receptors].

  G. Le Fur, M. Rinaldi-Carmona, F. Barth, & J. Alexander. (2007)

  Bulletin de l’Académie nationale de médecine, 191(4-5), 933-8;discussion938–40.
• 2005
• CB1 Cannabinoid Receptor Antagonists

  F. Barth. (2005)

  In Annual Reports in Medicinal Chemistry Volume 40 (Vol. 40, p. 103–118)Elsevier.
• Cannabinoids in appetite and obesity

  F. Barth, & M. Rinaldi-Carmona. (2005)

  (R. Mechoulam, Eds.) Cannabinoids as Therapeutics (p. 219–230)Basel: Birkhäuser-Verlag.
• 2004
• SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor

  M. Rinaldi-Carmona, F. Barth, C. Congy, S. Martinez, D. Oustric, A. Pério, .... (2004)

  The Journal of pharmacology and experimental therapeutics, 310(3), 905-14.
• 2002
• International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

  A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, .... (2002)

  Pharmacological reviews, 54(2), 161-202.
• The cannabinoid receptors and their interactions with synthetic cannabinoid agonists and antagonists

  F. Barth, G. Le Fur, B. Calandra, M. Rinaldi-Carmona, P. Casellas, P. Gouldson, .... (2002)

  (E. Onaivi, Eds.) The Biology of Marijuana (p. 10.1201/9780203219133.ch21)CRC Press.
• Carbon-11 labeled radioligands for imaging brain cannabinoid receptors

  W. B. Mathews, U. Scheffel, P. A. Rauseo, H. T. Ravert, R. A. Frank, G. J. Ellames, .... (2002)

  Nuclear Medicine and Biology, 29(6), 671–677.
• 2000
• Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB2 receptor

  P. Gouldson, B. Calandra, P. Legoux, A. Kernéis, M. Rinaldi-Carmona, F. Barth, .... (2000)

  European Journal of Pharmacology, 401(1), 17-25.
• Biodistribution of [18f] SR144385 and [18f] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors

  W. B. Mathews, U. Scheffel, P. Finley, H. T. Ravert, R. A. Frank, M. Rinaldi-Carmona, .... (2000)

  Nuclear Medicine and Biology, 27(8), 757–762.
• 1999
• SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist

  M. Portier, M. Rinaldi-Carmona, F. Pecceu, T. Combes, C. Poinot-Chazel, B. Calandra, .... (1999)

  J. Pharmacol. Exp. Ther., 288(2), 582-589.
• The development of cannabinoid antagonists.

  F. Barth, & M. Rinaldi-Carmona. (1999)

  Current medicinal chemistry, 6(8), 745-55.
• Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528

  D. Shire, B. Calandra, M. Bouaboula, F. Barth, M. Rinaldi-Carmona, P. Casellas, & P. Ferrara. (1999)

  Life Sciences, 65(6-7), 627–635.
• Synthesis of [18F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors

  W. B. Mathews, H. T. Ravert, J. L. Musachio, R. A. Frank, M. Rinaldi-Carmona, F. Barth, & R. F. Dannals. (1999)

  Journal of Labelled Compounds and Radiopharmaceuticals, 42(6), 589–596.
• 1998
• Modulation of CB1 Cannabinoid Receptor Functions after a Long-Term Exposure to Agonist or Inverse Agonist in the Chinese Hamster Ovary Cell Expression System

  M. Rinaldi-Carmona, A. Le Duigou, D. Oustric, F. Barth, M. Bouaboula, P. Carayon, .... (1998)

  J. Pharmacol. Exp. Ther., 287(3), 1038-1047.
• SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor

  M. Rinaldi-Carmona, F. Barth, J. Millan, J. - M. Derocq, P. Casellas, C. Congy, .... (1998)

  J. Pharmacol. Exp. Ther., 284(2), 644-650.
• Cannabinoid receptor agonists and antagonists

  F. Barth. (1998)

  Expert Opinion on Therapeutic Patents, 8(3), 301–313.
• 1997
• A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS

  M. Bouaboula, & al. (1997)

  Journal of Biological Chemistry, 272(35), 22330-22339.
• 1996
• Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain

  M. Rinaldi-Carmona, F. Pialot, C. Congy, E. Redon, F. Barth, A. Bachy, .... (1996)

  Life Sciences, 58(15), 1239-1247.
• Characterization of two cloned human CB1 cannabinoid receptor isoforms

  M. Rinaldi-Carmona, B. Calandra, D. Shire, M. Bouaboula, D. Oustric, F. Barth, .... (1996)

  J. Pharmacol. Exp. Ther., 278(2), 871-878.
• Central mediation of the cannabinoid cue

  A. Pério, M. Rinaldi-Carmona, J. Maruani, F. Barth, G. Le Fur, & P. Soubrié. (1996)

  Behavioural pharmacology, 7(1), 65-71.
• 1995
• Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonist

  M. Rinaldi-Carmona, F. Barth, M. Héaulme, R. Alonso, D. Shire, C. Congy, .... (1995)

  Life Sciences, 56(23-24), 1941–1947.
• 1994
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, C. Congy, .... (1994)

  FEBS Letters, 350(2-3), 240-244.
• 1993
• Synthèse totale de la Dihydro-2,3-illudine M par cycloaddition d'enamine sur cyclopropene.

  M. Franck-Neumann, M. Miesch, & F. Barth. (1993)

  Tetrahedron, 49(7), 1409–1420.
• 1991
• Cyclization of α,α-Difluoromethyl Radicals: A New Route to the Preparation of Difluorocyclopentane Derivatives

  F. Barth, & C. O-Yang. (1991)

  Tetrahedron Letters, 32(42), 5873–5876.
• 1990
• Radical cyclizatations of α-fluoro-α-iodo and α-iodo esters and amides.

  F. Barth, & C. O-Yang. (1990)

  Tetrahedron Letters, 31(8), 1121–1124.
• 1989
• De l’instabilité des cyclopropènes à double liaison fonctionnalisée monosubstituée

  M. FRANCK-NEUMANN, M. MIESCH, F. BARTH, & G. JENNER. (1989)

  Bulletin de la Société chimique de France, (5), 661-666.
• Synthese cyclopropenique de derives de l’illudine M

  M. Franck-Neumann, M. Miesch, & F. Barth. (1989)

  Tetrahedron Letters, 30(27), 3537-3540.
• 1988
• Reactions de cyclobutenes electrophiles avec les enamines

  M. Franck-Neumann, M. Miesch, & F. Barth. (1988)

  Tetrahedron, 44(2), 417-428.